Delergotrile

Delergotrile
Clinical data
Other namesCM 29-712; CM-29712; CM29-712; 6-Methylergoline-8α-acetonitrile; 6-Methyl-8α-(cyanomethyl)ergoline
Drug classDopamine receptor agonist; Antiparkinsonian agent
ATC code
  • None
Identifiers
  • 2-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H19N3
Molar mass265.360 g·mol−1
3D model (JSmol)
  • CN1C[C@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CC#N
  • InChI=1S/C17H19N3/c1-20-10-11(5-6-18)7-14-13-3-2-4-15-17(13)12(9-19-15)8-16(14)20/h2-4,9,11,14,16,19H,5,7-8,10H2,1H3/t11-,14+,16+/m0/s1
  • Key:LBMFWYCMCHRLBU-SGIREYDYSA-N

Delergotrile (INNTooltip International Nonproprietary Name; developmental code name CM 29-712), also known as 6-methylergoline-8α-acetonitrile, is a dopamine receptor agonist of the ergoline family described as an antiparkinsonian agent which was never marketed. It is an analogue of lergotrile (LY-79907).

The drug shows high affinity for the dopamine D2 receptor (Ki = 34 nM). In addition to dopamine receptors, delergotrile shows affinity for the serotonin 5-HT1 receptor (K0.5 = 2.0 nM) and for the serotonin 5-HT2 receptor (Ki = 57 nM), as well as for the α1- and α2-adrenergic receptors. The drug appears to be an agonist of both dopamine D1 and to a lesser extent D2 receptors. Due to its dopamine receptor agonism, delergotrile produces antiparkinsonian-like effects, induces changes in locomotor activity and stereotypy, and reverses reserpine-induced akinesia in rodents. It also produces effects consistent with weak blockade of α-adrenergic receptors in rodents.

Delergotrile was first described in the literature by 1976. It was developed by Sandoz.